Theravance Biopharma Inc (NASDAQ:TBPH) has earned an average recommendation of “Hold” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $41.33.

TBPH has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. Cantor Fitzgerald reissued a “buy” rating and issued a $55.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, September 19th. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Robert W. Baird reissued a “sell” rating and issued a $22.00 price objective on shares of Theravance Biopharma in a research report on Wednesday, November 1st. Finally, Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday, December 5th.

Theravance Biopharma (NASDAQ:TBPH) opened at $26.98 on Monday. Theravance Biopharma has a 12-month low of $23.15 and a 12-month high of $43.44. The company has a market cap of $1,460.00, a PE ratio of -5.23 and a beta of 2.35. The company has a debt-to-equity ratio of 1.21, a current ratio of 7.53 and a quick ratio of 7.21.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.05). Theravance Biopharma had a negative net margin of 1,604.87% and a negative return on equity of 99.43%. sell-side analysts expect that Theravance Biopharma will post -4.84 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in the stock. Moneta Group Investment Advisors LLC bought a new stake in shares of Theravance Biopharma during the 3rd quarter worth about $299,000. Schwab Charles Investment Management Inc. boosted its holdings in shares of Theravance Biopharma by 8.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 191,558 shares of the biopharmaceutical company’s stock worth $6,559,000 after buying an additional 14,241 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Theravance Biopharma by 32.0% during the 3rd quarter. Wells Fargo & Company MN now owns 117,079 shares of the biopharmaceutical company’s stock worth $4,009,000 after buying an additional 28,391 shares during the period. Legal & General Group Plc boosted its holdings in shares of Theravance Biopharma by 15.7% during the 3rd quarter. Legal & General Group Plc now owns 18,840 shares of the biopharmaceutical company’s stock worth $646,000 after buying an additional 2,551 shares during the period. Finally, American International Group Inc. boosted its holdings in shares of Theravance Biopharma by 8.1% during the 3rd quarter. American International Group Inc. now owns 28,000 shares of the biopharmaceutical company’s stock worth $959,000 after buying an additional 2,094 shares during the period. 86.02% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/15/theravance-biopharma-inc-tbph-given-average-rating-of-hold-by-brokerages.html.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.